Adicet Bio, Inc.
NASDAQ:ACETBiotechnology
+$0.02 today
- Market cap
- $51.70M
- Beta
- 1.57
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$10.13
Volume 0.15M
Average 0.12M
ACET Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Adicet Bio, Inc.NASDAQ: ACET
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $1.3M fell 59.0% year over year, behind the -37.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 76.9% from the prior quarter. Over 3 fiscal years it compounded at -5.9% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -59.0% toward the trailing-twelve-month pace of -37.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 14.27M USD
- Year-over-year change
- -35.8%
- 4-year CAGR
- +3.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.27M | -35.8% |
| FY2024 | 2024-12-31 | 22.23M | +9.7% |
| FY2023 | 2023-12-31 | 20.26M | +18.3% |
| FY2022 | 2022-12-31 | 17.13M | +36.9% |
| FY2021 | 2021-12-31 | 12.51M | — |
Stock-Based Compensation vs competitors
How ACET compares with its peers on the latest reported figures
- ACET's LTM Mar 2026 stock-based compensation of $12.39M is the 2nd largest of the 8 companies compared; the peer median is $7.27M.
- Its year-over-year change of -37.2% is the 6th highest of 7, against a peer median of -6.5%.
- Over three fiscal years its annual growth of -5.9% compares with a peer median of +3.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $13.11M | -11.0% | +88.9% | — |
| LTM Mar 2026 | $12.39M | -37.2% | -5.9% | — | |
| LTM Mar 2026 | $11.29M | +44.4% | +3.8% | — | |
| LTM Mar 2026 | $10.76M | -2.0% | +37.0% | 117.7% | |
| LTM Jun 2024 | $7.27M | — | -29.1% | 891.4% | |
| LTM Jun 2026 | $3.79M | -50.8% | -5.5% | 18.1% | |
| LTM Mar 2026 | $1.79M | -31.8% | +5.7% | — | |
| LTM Mar 2026 | $367K | +43.4% | -60.2% | 16.0% | |
| Peer median (excluding ACET) | $7.27M | -6.5% | +3.8% | 67.9% | |
Competitors are the stored peer set for ACET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (62M) | (69.79M) | (142.66M) | (117.12M) | (116.8M) |
| Depreciation & Amortization | 1.54M | 2.58M | 6.1M | 6.47M | 2.29M |
| Deferred Income Tax | 1.23M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 12.51M | 17.13M | 20.26M | 22.23M | 14.27M |
| Change in Working Capital | (6.06M) | 2.74M | 252K | (5.53M) | 1.47M |
| Accounts Receivables | (30K) | 185K | 0 | 0 | 0 |
| Inventory | 2.01M | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.14M | 1.71M | (1.68M) | 1.11M | 1.03M |
| Other Working Capital | (9.18M) | 849K | 1.94M | (6.63M) | 444K |
| Other Non-Cash Items | 1.72M | 2.58M | 22.33M | 1.57M | 3.53M |
| Operating Cash Flow | (51.05M) | (44.77M) | (93.72M) | (92.38M) | (95.25M) |
| Capital Expenditures | (13.05M) | (16.78M) | (4.46M) | (1.12M) | (1.74M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (129.12M) | (140.87M) |
| Sales of Investments | 10.25M | 0 | 0 | 11M | 145M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (2.8M) | (16.78M) | (4.46M) | (119.24M) | 2.39M |
| Debt Repayment | 0 | 0 | 0 | 0 | (150K) |
| Common Stock Issued | 238.13M | 43.36M | 386K | 110.92M | 75.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.56M | (1.85M) | (150K) | 389K | (104K) |
| Financing Cash Flow | 242.69M | 41.51M | 236K | 111.31M | 75.25M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 188.84M | (20.04M) | (97.95M) | (100.31M) | (17.61M) |
| Free Cash Flow | (64.1M) | (61.55M) | (98.18M) | (93.5M) | (96.98M) |
Adicet Bio, Inc.
NASDAQ:ACET
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.